Mark T. Fleming
Expertise in
22
conditions

Dr. Mark T. Fleming

Hematology
3000 Coliseum Drive, Suite 104, 
Hampton, VA 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
3000 Coliseum Drive, Suite 104, 
Hampton, VA 

Overview

Mark Fleming is a Hematologist practicing medicine in Hampton, Virginia.

Dr. Fleming is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Agranulocytosis, Pancreaticoduodenectomy, and Orchiectomy.

Dr. Fleming is board certified in American Board Of Internal Medicine - Medical Oncology - 2027. He is actively involved in clinical research, co-authoring 40 peer reviewed articles and participating in 9 clinical trials. Dr. Fleming is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in VA

Board Certifications

American Board Of Internal Medicine - Medical Oncology - 2027

Fellowships

Memorial Sloan-Kettering Cancer Center - 2006

Hospital Affiliations

SQCN Provider
Sentara Leigh Hospital
Sentara Norfolk General Hospital
Sentara Virginia Beach General Hospital
Sentara Careplex Hospital
Chesapeake General Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Optima Health
  • HMO
  • POS
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Virginia Oncology Associates
3000 Coliseum Drive, Suite 104, Hampton, VA 23666

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-Directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2026
Intervention Type: Drug
Study Drug: ARDT
Study Phase: Phase 3
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Drug
Study Drugs: 177Lu-PSMA-617, Androgen Receptor Directed Therapy, Androgen Deprivation Therapy
Study Phase: Phase 3
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Enrollment Status: Completed
Publish Date: April 06, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

40 Total Publications

TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.
Journal: Future oncology (London, England)
Published: May 16, 2026
Similar Doctors
Expertise in
40
conditions
Expertise in
40
conditions
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (20.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mrinal Patnaik is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Patnaik is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Patnaik is currently accepting new patients.

Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (20.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Animesh Pardanani is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Pardanani is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Systemic Mastocytosis, Essential Thrombocythemia, Splenectomy, and Bone Marrow Aspiration. Dr. Pardanani is currently accepting new patients.

Expertise in
17
conditions
Dr. Gaurav Goyal
Hematology
Expertise in
17
conditions
Dr. Gaurav Goyal
Hematology
Referral may be required

Mayo Clinic-Rochester

5716 Cleveland St Ste 200, 
Virginia Beach, VA 
 (20.1 miles away)
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gaurav Goyal is a Hematologist practicing medicine in Virginia Beach, Virginia. Dr. Goyal is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Histiocytosis, Reticulohistiocytoma, Non-Langerhans-Cell Histiocytosis, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Goyal is currently accepting new patients.

Frequently Asked Questions about Dr. Mark T. Fleming

How do I make an appointment with Dr. Mark T. Fleming?

You can book an appointment with Dr. Mark T. Fleming by calling their office at 757-873-9800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark T. Fleming a top-rated expert for Muscle Invasive Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark T. Fleming is classified as an Distinguished expert for Muscle Invasive Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark T. Fleming specialize in?

While Dr. Mark T. Fleming is a Hematology, they have specific expertise in Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, and Agranulocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mark T. Fleming participate in research or clinical trials?

Yes. Dr. Mark T. Fleming has published 40 articles and abstracts on conditions like Muscle Invasive Bladder Cancer. You can view a list of Dr. Mark T. Fleming's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark T. Fleming accept my insurance?

Dr. Mark T. Fleming accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 757-873-9800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fleming's expertise for a condition
ConditionClose
    View All 16 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile